Status:
COMPLETED
Study of Quetiapine Treatment for Cannabis Dependence
Lead Sponsor:
New York State Psychiatric Institute
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Cannabis Dependence
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Marijuana is the most commonly used illicit drug in the United States. However, the treatment options for cannabis dependence are limited; notably, no effective pharmacotherapy has been developed. Con...
Detailed Description
Conceptually, the pharmacodynamic and clinical actions of quetiapine suggest that it may be useful for cannabis dependence. By antagonizing dopamine, quetiapine may interfere with the reinforcing effe...
Eligibility Criteria
Inclusion
- Between the ages of 18-65
- Meets DSM-IV criteria for current cannabis dependence
- Seeking treatment for cannabis dependence
- Reports using cannabis an average of five days per week over the past 28 days
- Capable of giving informed consent and complying with study procedures
Exclusion
- Lifetime history of DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder
- Current DSM-IV criteria for any other psychiatric disorder that may, according to the investigator's judgment, require either pharmacological or non-pharmacological intervention over the course of the study
- Receiving prescribed psychotropic medication
- Known history of allergy, intolerance, or hypersensitivity to quetiapine
- Pregnancy, lactation, or failure to use adequate contraceptive methods in female patients who are currently engaging in sexual activity with men
- Unstable medical conditions, such as poorly controlled diabetes or hypertension, which might make participation hazardous
- Current DSM-IV diagnosis of substance dependence other than cannabis or nicotine dependence
- Are legally mandated to participate in a substance use disorder treatment program
- Increased risk for suicide
- Diabetes (whether controlled or not), hyperglycemia (fasting glucose \> 100 mg/dl), obesity (BMI \> 30) and elevated lipids (cholesterol \> 200 mg/dl; triglycerides \> 150 mg/dl).
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00954681
Start Date
August 1 2009
End Date
August 1 2010
Last Update
April 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Substance Treatment Research Service (STARS) of Columbia University
New York, New York, United States, 10032